Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study.

Eldor R, Arbit E, Corcos A, Kidron M.

PLoS One. 2013 Apr 9;8(4):e59524. doi: 10.1371/journal.pone.0059524. Print 2013.

2.
3.
4.

Efficacy of real-time continuous glucose monitoring on glycaemic control and glucose variability in type 1 diabetic patients treated with either insulin pumps or multiple insulin injection therapy: a randomized controlled crossover trial.

Tumminia A, Crimi S, Sciacca L, Buscema M, Frittitta L, Squatrito S, Vigneri R, Tomaselli L.

Diabetes Metab Res Rev. 2015 Jan;31(1):61-8. doi: 10.1002/dmrr.2557.

PMID:
24816997
5.

2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.

Kropff J, Del Favero S, Place J, Toffanin C, Visentin R, Monaro M, Messori M, Di Palma F, Lanzola G, Farret A, Boscari F, Galasso S, Magni P, Avogaro A, Keith-Hynes P, Kovatchev BP, Bruttomesso D, Cobelli C, DeVries JH, Renard E, Magni L; AP@home consortium.

Lancet Diabetes Endocrinol. 2015 Dec;3(12):939-47. doi: 10.1016/S2213-8587(15)00335-6. Epub 2015 Sep 30.

PMID:
26432775
6.

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

Diabetes Care. 2003 Nov;26(11):3074-9.

PMID:
14578242
7.

Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring.

Matsuura K, Mori Y, Nakamura A, Yokoyama J, Utsunomiya K.

Diabetes Technol Ther. 2012 May;14(5):423-9. doi: 10.1089/dia.2011.0188. Epub 2012 Feb 8.

PMID:
22316114
8.

Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.

Testa MA, Gill J, Su M, Turner RR, Blonde L, Simonson DC.

J Clin Endocrinol Metab. 2012 Oct;97(10):3504-14. doi: 10.1210/jc.2012-1763. Epub 2012 Jul 31.

PMID:
22851487
9.

Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.

Kipnes M, Dandona P, Tripathy D, Still JG, Kosutic G.

Diabetes Care. 2003 Feb;26(2):421-6.

PMID:
12547873
10.

Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.

Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.

Rom J Intern Med. 2003;41(2):153-62.

PMID:
15526500
11.

Comparison of oral insulin spray and subcutaneous regular insulin at mealtime in type 1 diabetes.

Guevara-Aguirre J, Guevara-Aguirre M, Saavedra J, Bernstein G, Rosenbloom AL.

Diabetes Technol Ther. 2007 Aug;9(4):372-6.

PMID:
17705693
12.

Accuracy assessment of online glucose monitoring by a subcutaneous enzymatic glucose sensor during exercise in patients with type 1 diabetes treated by continuous subcutaneous insulin infusion.

Radermecker RP, Fayolle C, Brun JF, Bringer J, Renard E.

Diabetes Metab. 2013 May;39(3):258-62. doi: 10.1016/j.diabet.2012.12.004. Epub 2013 Mar 19.

13.

Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.

Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C.

Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):571-9. doi: 10.1016/j.numecd.2008.05.003. Epub 2008 Aug 3.

PMID:
18676131
15.

Restoring euglycemia in the basal state using continuous glucose monitoring in subjects with type 1 diabetes mellitus.

Zisser HC, Bevier WC, Jovanovic L.

Diabetes Technol Ther. 2007 Dec;9(6):509-15.

PMID:
18034605
17.

Glycemic Variability Is Associated with Frequency of Blood Glucose Testing and Bolus: Post Hoc Analysis Results from the ProAct Study.

Pfützner A, Weissmann J, Mougiakakou S, Daskalaki E, Weis N, Ziegler R.

Diabetes Technol Ther. 2015 Jun;17(6):392-7. doi: 10.1089/dia.2014.0278. Epub 2015 Mar 3.

18.

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.

Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, Bogle A, Iqbal N, List J, Griffen SC.

Diabetes Care. 2015 Mar;38(3):412-9. doi: 10.2337/dc13-2955. Epub 2014 Sep 30.

PMID:
25271207
19.

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.

Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR.

Diabetes Care. 2003 Jan;26(1):1-8.

PMID:
12502651
20.

Responses to continuous glucose monitoring in subjects with type 1 diabetes using continuous subcutaneous insulin infusion or multiple daily injections.

Rodbard D, Jovanovic L, Garg SK.

Diabetes Technol Ther. 2009 Dec;11(12):757-65. doi: 10.1089/dia.2009.0078.

PMID:
20001676

Supplemental Content

Support Center